HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Abstract
Glatiramer acetate is a synthetic, random copolymer widely used as a first-line agent for the treatment of relapsing-remitting multiple sclerosis (MS). While earlier studies primarily attributed its clinical effect to a shift in the cytokine secretion of CD4+ T helper (T(h)) cells, growing evidence in MS and its animal model, experimental autoimmune encephalomyelitis (EAE), suggests that glatiramer acetate treatment is associated with a broader immunomodulatory effect on cells of both the innate and adaptive immune system. To date, glatiramer acetate-mediated modulation of antigen-presenting cells (APC) such as monocytes and dendritic cells, CD4+ T(h) cells, CD8+ T cells, Foxp3+ regulatory T cells and antibody production by plasma cells have been reported; in addition, most recent investigations indicate that glatiramer acetate treatment may also promote regulatory B-cell properties. Experimental evidence suggests that, among these diverse effects, a fostering interplay between anti-inflammatory T-cell populations and regulatory type II APC may be the central axis in glatiramer acetate-mediated immune modulation of CNS autoimmune disease. Besides altering inflammatory processes, glatiramer acetate could exert direct neuroprotective and/or neuroregenerative properties, which could be of relevance for the treatment of MS, but even more so for primarily neurodegenerative disorders, such as Alzheimer's or Parkinson's disease. In this review, we provide a comprehensive and critical overview of established and recent findings aiming to elucidate the complex mechanism of action of glatiramer acetate.
AuthorsPatrice H Lalive, Oliver Neuhaus, Mahdia Benkhoucha, Danielle Burger, Reinhard Hohlfeld, Scott S Zamvil, Martin S Weber
JournalCNS drugs (CNS Drugs) Vol. 25 Issue 5 Pg. 401-14 (May 2011) ISSN: 1179-1934 [Electronic] New Zealand
PMID21476611 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Immunosuppressive Agents
  • Neuroprotective Agents
  • Peptides
  • Glatiramer Acetate
Topics
  • Animals
  • Disease Models, Animal
  • Encephalomyelitis, Autoimmune, Experimental (drug therapy, immunology)
  • Female
  • Glatiramer Acetate
  • Humans
  • Immunosuppressive Agents (pharmacology)
  • Male
  • Mice
  • Multiple Sclerosis (drug therapy, immunology)
  • Multiple Sclerosis, Relapsing-Remitting (drug therapy, immunology)
  • Neuroprotective Agents (pharmacology)
  • Peptides (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: